VolitionRX Limited

Good morning, ladies and gentlemen. Thank you for standing by. Welcome to VolitionRx Limited's first quarter 2021 earnings conference call. During today's presentation, all parties will be in a listen-only mode. Following the presentation, the conference call will be open for questions. If you have a question, please press star key followed by the number one on your touchtone phone. If you would like to withdraw your question, please press star key followed by the number two. If you're using speaker equipment, please lift the handset before making your selections. This conference call is being recorded today, May 12th, 2021. I'd now like to turn the conference call over to Scott Powell, Executive Vice President of Investor Relations. Please go ahead.

Thank you and welcome everyone to today's earnings conference call. for VolitionRx Limited. This call will cover Volition's financial and operating results for the first quarter of 2021, along with a discussion of our recent activities and key upcoming milestones. Following our prepared remarks, we will open the conference call to a question and answer session. On our call today is Mr. Cameron Reynolds, President and Chief Executive Officer, and Mr. Terry Cuse, our Chief Financial Officer. Before we begin, I'd like to remind everyone that some of the information discussed on this conference call will include forward-looking statements covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on our beliefs as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties, and assumptions. Actual future results may vary significantly based on a number of factors that may cause the actual results or events to be materially different from future results, performance, or achievements expressed or implied by these statements. We have identified various risk factors associated with our operations in our most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and other filings with the Securities and Exchange Commission. We do not undertake an obligation to update any forward-looking statements made during the course of this call. I would now like to turn the call over to our President and Chief Executive Officer, Mr. Cameron Reynolds. Cameron?

Thank you, everyone, for joining Volition's conference call today. I especially appreciate it given the busy earnings call season. And speaking of busy, wow, we have had quite a start to the year and have made excellent progress in developing a range of products based on our proprietary NUQ platform. I expect that we will have a lot of news throughout the remainder of this year on additional product developments worldwide. I will be updating you today on our products, people, patents, publications, and most importantly, progress within all four key pillars, NUQ Cancer, NUQ Vet, NUQ Nets, and NUQ Capture. But to start off, I'll quickly hand over to Tereg for the financial report.